Catalyst Financial Partners LLC Purchases 33 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Catalyst Financial Partners LLC raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,639 shares of the medical equipment provider’s stock after acquiring an additional 33 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Intuitive Surgical were worth $553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Intuitive Surgical by 0.7% in the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after purchasing an additional 196,316 shares in the last quarter. Jennison Associates LLC increased its stake in Intuitive Surgical by 6.4% in the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock worth $1,340,205,000 after buying an additional 274,692 shares in the last quarter. Fisher Asset Management LLC lifted its position in shares of Intuitive Surgical by 2.0% in the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after acquiring an additional 88,977 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Intuitive Surgical by 6.6% in the third quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock worth $1,096,231,000 after acquiring an additional 232,205 shares during the period. Finally, Northern Trust Corp raised its stake in Intuitive Surgical by 3.4% during the 3rd quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider’s stock valued at $1,027,230,000 after purchasing an additional 115,059 shares during the period. Institutional investors own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In related news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at $736,800. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 147,927 shares of company stock valued at $57,064,459. Company insiders own 0.80% of the company’s stock.

Intuitive Surgical Stock Up 1.3 %

ISRG traded up $5.08 on Thursday, reaching $385.45. 882,172 shares of the company traded hands, compared to its average volume of 1,594,653. The company has a market cap of $136.72 billion, a P/E ratio of 69.58, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The firm has a fifty day simple moving average of $385.21 and a two-hundred day simple moving average of $352.17.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.00 earnings per share. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on ISRG shares. BTIG Research upped their price target on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. Wells Fargo & Company raised their price objective on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research report on Friday, January 19th. Citigroup raised their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Robert W. Baird cut their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Finally, Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.